ChemoMetec Stock price
Compare with Peer Group
📊 Peer Group
📈 What is it?
The peer group consists of the companies with the most similar business model. They serve as a benchmark for putting a stock into context.
🧮 How is it selected?
Based on similarity of business model, meaning companies from the same industry with comparable products and a similar customer base. That's the only way to compare apples to apples.
🏛️ Why does it matter?
Whether a stock is cheap or expensive is best judged by comparison. A P/E of 18 or an EV/FCF of 20 can look cheap or expensive depending on the yardstick. The peer group gives you the most accurate one: companies with a similar business model that operate under the same conditions.
🎯 What does it mean for investors?
When a metric sits below the peer average, the stock is valued more cheaply relative to its competitors, and above the average more expensively. A discount to the peer group can be an opportunity, but it can also have a reason (for example lower growth). The comparison is a starting point, not a verdict.
Is ChemoMetec a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.
StocksGuide Premium
StocksGuide Unlimited
Key metrics
📘 Market Capitalization
📈 What is it?
Market capitalization shows how much a company is currently worth on the stock market.
🧮 How is it calculated?
🏛️ Why is it important?
It helps classify companies by size (Large, Mid, Small Cap) and indicates their market presence and relative stability.
🧮 Calculation
🎯 What does this mean for investors?
- Large-cap companies tend to be more stable, often pay dividends, but may grow more slowly.
- Smaller firms may offer higher growth potential but come with more volatility.
- Market capitalization is a useful indicator of company size — but not a measure of whether a stock is undervalued or overvalued.
📘 Enterprise Value (EV)
📈 What is it?
Enterprise Value represents the total cost to acquire a company — including its debt and excluding its cash reserves.
🧮 How is it calculated?
(= Market Cap + Net Debt)
🏛️ Why is it important?
EV gives a more complete picture of a company's value than market cap alone and is used in key valuation ratios like EV/FCF or EV/Sales.
🧮 Calculation
🎯 What does this mean for investors?
- Enterprise Value shows the true cost of buying a company, including all financial obligations.
- It is more accurate than just looking at market cap, especially when comparing companies with different levels of debt or cash.
- Professional investors prefer EV-based multiples because they better reflect the company’s full financial footprint.
📘 Net Debt
📈 What is it?
Net Debt shows how much debt remains after subtracting a company’s available cash reserves.
🧮 How is it calculated?
🏛️ Why is it important?
It indicates how dependent a company is on borrowed money and how easily it can service its debt in the short term.
🧮 Calculation
🎯 What does this mean for investors?
- Low or negative net debt signals financial strength and flexibility.
- Companies with strong cash positions are better positioned in crises.
- High net debt increases financial risk — especially in environments with rising interest rates or economic downturns.
📘 Cash
📈 What is it?
Cash represents all liquid assets a company can access immediately — including cash, bank deposits, and short-term investments.
🧮 How is it calculated?
🏛️ Why is it important?
It reflects a company’s financial flexibility and resilience — enabling investments, buybacks, or buffer in downturns.
🧮 Calculation
🎯 What does this mean for investors?
- A strong cash position means greater room for maneuver and crisis resistance.
- Cash-rich companies can invest, pay down debt, or repurchase shares.
- But excess idle cash might indicate a lack of growth opportunities.
📘 Shares Outstanding
📈 What is it?
Shares outstanding represent the total number of a company’s shares currently held by investors — excluding treasury stock.
🧮 How is it calculated?
🏛️ Why is it important?
It’s the basis for key metrics like Earnings Per Share (EPS), Market Capitalization, or the Price/Earnings ratio (P/E).
🧮 Calculation
🎯 What does this mean for investors?
- Fewer shares in circulation typically increase earnings per share — making each share more valuable.
- Share buybacks reduce the number of shares and boost per-share metrics.
- Issuing new shares does the opposite — diluting shareholder value and lowering per-share figures.
📘 Price-to-Earnings Ratio (P/E)
📈 What is it?
The P/E ratio shows how many times a company's earnings per share are reflected in its current share price — in other words, how "expensive" the stock appears relative to its profits.
🧮 How is it calculated?
🏛️ Why is it important?
The P/E ratio is one of the most widely used valuation metrics. It helps investors assess whether a stock appears cheap or expensive compared to its earnings power.
🧮 Calculation
📊 P/E (TTM) = Based on earnings from the last 12 months (Trailing Twelve Months):🎯 What does this mean for investors?
- A low P/E may indicate undervaluation — or signal underlying issues.
- A high P/E may reflect strong growth expectations — or an overvalued stock.
📘 Price-to-Sales Ratio (P/S)
📈 What is it?
The P/S ratio shows how much investors are paying for $1 of the company’s revenue – regardless of profitability.
🧮 How is it calculated?
🏛️ Why is it important?
P/S is especially useful for evaluating growth companies or businesses not yet profitable. It reflects how the market values the company’s sales.
🧮 Calculation
Market Cap = kr11.98b | Revenue (TTM) = kr511.06m
Market Cap = kr11.98b | Estimated Revenue = kr599.98m
🎯 What does this mean for investors?
- A low P/S may indicate undervaluation — or low profitability.
- A high P/S can reflect strong growth expectations — or excessive optimism.
- Especially helpful when evaluating companies where profits are low, volatile, or negative.
📘 Enterprise Value to Sales (EV/Sales)
📈 What is it?
EV/Sales shows how much investors are paying for $1 of revenue — considering not just equity, but also debt and cash. It’s the capital structure–adjusted version of the P/S ratio.
🧮 How is it calculated?
🏛️ Why is it important?
It’s ideal for comparing companies with different levels of debt. It reflects a company's true cost relative to its revenue.
🧮 Calculation
Enterprise Value = kr11.69b | Revenue (TTM) = kr511.06m
Enterprise Value = kr11.69b | Forward Revenue = kr599.98m
🎯 What does this mean for investors?
- EV/Sales allows for capital structure–neutral company comparisons.
- A lower ratio may indicate undervaluation; a higher one may signal strong growth expectations or overvaluation.
- Especially helpful when evaluating high-growth companies with low or negative earnings.
📘 Enterprise Value to Free Cash Flow (EV/FCF) | ex SBC
📈 What is it?
EV/FCF compares a company’s enterprise value with its free cash flow. The metric therefore shows the multiple of current free cash flow at which a company is valued. EV/FCF ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted version.
🧮 How is it calculated?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cash Flow (TTM) − SBC)
🏛️ Why is it important?
EV/FCF provides a valuation based on free cash flow and therefore complements earnings-based valuation metrics such as the P/E ratio. The ex SBC version additionally accounts for the economic impact of stock-based compensation and provides a more conservative view from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A low EV/FCF means that enterprise value is low relative to current free cash flow. The reasons should always be considered in the context of the company and its industry.
- A high EV/FCF means that enterprise value is high relative to current free cash flow. This can, for example, reflect high growth expectations or temporarily weak cash generation.
- When SBC is positive and adjusted free cash flow remains positive, EV/FCF ex SBC is generally higher than the standard EV/FCF.
- The metric is particularly useful for companies with relatively stable and predictable cash flows.
- If free cash flow is negative or very low, EV/FCF has limited usefulness and should not be interpreted like a standard valuation multiple.
📘 Price-to-Book Ratio (P/B)
📈 What is it?
The P/B ratio compares a company’s market value to its book value — showing how much investors are paying for each dollar of net assets.
🧮 How is it calculated?
🏛️ Why is it important?
P/B is commonly used for asset-heavy industries like banks or industrials. It helps assess whether a stock is trading above or below its net asset value.
🧮 Calculation
🎯 What does this mean for investors?
- A P/B below 1 may signal undervaluation — or weak profitability.
- A P/B above 1 implies the market expects future value creation (e.g., brand, IP, growth).
- Best used for companies with tangible assets and strong balance sheets.
📘 Dividend per Share (DPS)
📈 What is it?
Dividend per Share shows how much cash a company pays out to shareholders for each share they own – usually on an annual or quarterly basis.
🧮 How is it calculated?
🏛️ Why is it important?
DPS is the absolute value of the payout per share – crucial for income-focused investors and dividend strategies.
🧮 Calculation
🎯 What does this mean for investors?
- A stable or growing DPS often signals a strong, shareholder-friendly business.
- DPS alone doesn’t tell you how attractive the payout is – the stock price also matters (→ see Dividend Yield).
- Long-term dividend growth is often a hallmark of high-quality companies – like the dividend aristocrats.
📘 Dividend Yield
📈 What is it?
Dividend yield shows how large a company’s dividend is in relation to its current share price.
🧮 How is it calculated?
🏛️ Why is it important?
It allows investors to compare dividend payouts across stocks, regardless of price or payout size.
🧮 Calculation
🎯 What does this mean for investors?
- A stable yield can reflect reliable distributions.
- Comparing 1Y and 5Y yield shows whether dividend growth keeps pace with stock price appreciation.
- A low yield isn’t always negative – it can signal strong past performance or growth focus.
📘 Dividend Growth
📈 What is it?
Dividend growth shows how much a company has increased its dividend per share over time.
🧮 How is it calculated?
5Y: Compound Annual Growth Rate (CAGR)
🏛️ Why is it important?
Consistently rising dividends are often a sign of financial strength and shareholder orientation – especially relevant for long-term investors.
🧮 Calculation
🎯 What does this mean for investors?
- Stable dividend growth is a sign of sustainable earning power.
- High dividend growth can significantly boost your total return:
- If a company pays $1 in dividends and increases it by 15% annually over 5 years, you’ll receive $2 per share in year 5 – twice as much as at the start!
📘 Payout Ratio
📈 What is it?
The payout ratio shows what percentage of a company’s earnings (per share) is distributed to shareholders as dividends.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess whether the dividend is sustainable – especially in relation to the company’s profitability.
🧮 Calculation
🎯 What does this mean for investors?
- A low payout ratio means the company retains more earnings for reinvestment – typical for growth companies.
- A moderate payout (e.g. 25–50%) indicates a healthy balance between returns and reinvestment.
- High payout ratios may seem attractive but can carry risk if earnings decline.
📘 Consecutive Dividend Increases
📈 What is it?
This metric shows how many consecutive years a company has raised its dividend per share – without any cuts or pauses.
🧮 How is it calculated?
(Special dividends are not considered.)
🏛️ Why is it important?
A long track record of increases reflects financial strength, consistency, and shareholder commitment.
🎯 What does this mean for investors?
- A long dividend increase streak builds confidence – especially in volatile markets.
- Such companies are seen as reliable and income-friendly investments.
- The longer the streak, the stronger the company’s dividend discipline.
📘 Revenue
📈 What is it?
Revenue shows how much a company earns in total from selling its products and services – the gross income before any costs are deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Revenue is one of the key figures to assess a company’s size, market position, and growth potential.
🧮 Calculation
🎯 What does this mean for investors?
- Growing revenue indicates rising demand and can be an early signal of future earnings growth.
- Comparing actual and expected revenue reveals trends in the market environment and analyst sentiment.
- Note: Strong revenue alone isn’t enough – margins and profitability matter just as much.
📘 EBITDA
📈 What is it?
EBITDA stands for “Earnings Before Interest, Taxes, Depreciation, and Amortization.” It reflects a company’s operating profit before the effects of financing, taxes, and accounting depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
EBITDA is widely used to evaluate a company’s operating performance – especially across capital-intensive sectors or international comparisons.
🧮 Calculation
🎯 What does this mean for investors?
- A high or growing EBITDA indicates strong operational profitability – independent of taxes, interest, or accounting methods.
- It’s especially useful for comparing companies across sectors or geographies.
- Important: EBITDA is not a net income figure – it excludes key costs like depreciation and interest.
📘 EBIT
📈 What is it?
EBIT stands for “Earnings Before Interest and Taxes.” It reflects a company’s operating profit after depreciation, but before interest and tax expenses.
🧮 How is it calculated?
🏛️ Why is it important?
EBIT is a core profitability metric that shows how well the company performs in its main business operations – independent of capital structure and tax environment.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT indicates strong profitability from the company’s core business – before financial and tax effects.
- It allows better comparison between companies with different debt levels or tax structures.
- Compared to EBITDA, EBIT already accounts for depreciation and reflects capital intensity more clearly.
📘 Net Income
📈 What is it?
Net income is the company’s total profit – the amount left after all expenses, taxes, interest, and depreciation have been deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Net income is the most comprehensive measure of a company’s profitability – showing how much actual profit remains after all business and financing costs.
🧮 Calculation
🎯 What does this mean for investors?
- Growing net income indicates that the company is managing all of its costs efficiently.
- It directly influences valuation metrics like P/E ratio and the company’s dividend capacity.
- Over time, net income trends reveal how resilient and profitable the business model really is.
📘 Free Cash Flow (FCF) | ex SBC
📈 What is it?
Free cash flow shows how much cash remains after a company has covered its operating and capital expenditures. FCF ex SBC additionally deducts stock-based compensation (SBC) to adjust the cash flow for the effect of non-cash SBC.
🧮 How is it calculated?
Free Cash Flow ex SBC = Operating Cash Flow − SBC − Capital Expenditures (CAPEX)
🏛️ Why is it important?
FCF reflects a company’s actual financial strength – independent of reported accounting earnings. It shows how much flexibility a company has for dividends, share buybacks, or debt reduction. FCF ex SBC also deducts stock-based compensation and shows how much cash generation remains after SBC.
🧮 Calculation
🎯 What does this mean for investors?
- High free cash flow indicates that a company has strong financial strength – independent of reported earnings.
- It is often a solid basis for sustainable dividends and share buybacks.
- Declining FCF can be a warning sign, even if reported earnings remain stable.
📘 Revenue Growth
📈 What is it?
Revenue growth shows how much a company’s sales have changed compared to the previous year – both on a trailing basis (TTM) and based on forward projections.
🧮 How is it calculated?
Forward = (Expected revenue ÷ Revenue in prior year − 1) × 100
Forward growth is based on analyst estimates for the current fiscal year.
🏛️ Why is it important?
Rising revenue signals growing demand, business expansion, and market share gains – especially important for growth-oriented companies.
🧮 Calculation
🎯 What does this mean for investors?
- Growth is the engine of long-term value creation – especially in tech and growth sectors.
- What matters is not just current growth, but its sustainability.
- Forward projections reflect whether analysts expect continued momentum – or a slowdown.
📘 EBITDA Growth
📈 What is it?
EBITDA growth shows how much a company’s operating profit (before interest, taxes, depreciation, and amortization) has increased or decreased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBITDA ÷ EBITDA from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
Growing EBITDA indicates improving operational profitability – regardless of financing or accounting effects.
🧮 Calculation
🎯 What does this mean for investors?
- Strong EBITDA growth signals operational efficiency and scalability – especially during growth phases.
- EBITDA growth can be an early indicator of margin and earnings expansion – but should be assessed alongside revenue and EBIT.
📘 EBIT Growth
📈 What is it?
EBIT growth shows how much a company’s operating profit (after depreciation, but before interest and taxes) has increased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBIT ÷ EBIT from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
EBIT growth is a direct indicator of a company’s business performance – taking into account capital intensity through depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- Rising EBIT signals improving operating profitability – even after accounting for depreciation.
- It’s especially important for evaluating companies with significant capital expenditures.
- Combined with revenue and EBITDA growth, EBIT growth provides a well-rounded view of operational progress.
📘 Net Income Growth
📈 What is it?
Net income growth shows how much a company’s bottom-line profit has increased or decreased compared to the previous year – both on a trailing basis (TTM) and based on analyst projections.
🧮 How is it calculated?
Forward = (Expected net income ÷ Net income from prior year − 1) × 100
The forward estimate reflects analysts’ expectations for the current fiscal year.
🏛️ Why is it important?
Net income is the ultimate measure of profitability. Growing net income signals stronger efficiency, cost control, and sustainable earnings power.
🧮 Calculation
🎯 What does this mean for investors?
- Stronger net income boosts valuation, dividend potential, and investor confidence.
- If profits stall while revenue grows, it may signal margin pressure.
📘 Free Cash Flow Growth
📈 What is it?
Free cash flow (FCF) growth shows how a company’s available cash – after covering operating expenses and capital expenditures – has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
Free cash flow reflects real financial strength. Growing FCF indicates more flexibility for dividends, share buybacks, and reinvestment.
🧮 Calculation
🎯 What does this mean for investors?
- Declining FCF may point to rising investments, increasing costs, or weaker operating performance.
- Especially for dividend investors, FCF growth is critical – since dividends are paid from actual available cash.
- A negative trend isn't always bad, but it deserves closer attention.
📘 Gross Margin
📈 What is it?
Gross margin shows how much of a company’s revenue remains after deducting the direct costs of goods sold (like materials and production). It represents the company’s “raw profit” before fixed costs, taxes, and interest.
🧮 How is it calculated?
Or simply: Gross Margin = Gross Profit ÷ Revenue × 100
🏛️ Why is it important?
Gross margin indicates how efficiently a company can produce or procure what it sells. It is a key measure of product-level profitability and pricing power.
🧮 Calculation
🎯 What does this mean for investors?
- A high gross margin suggests strong pricing power and efficient production.
- Falling margins may signal rising input costs or competitive pressure.
- Compared to peers, gross margin offers insights into the quality of a business model.
📘 EBITDA Margin
📈 What is it?
The EBITDA margin shows how much of a company’s revenue remains as operating profit before interest, taxes, depreciation, and amortization.It reflects operating efficiency without being distorted by financing or accounting factors.
🧮 How is it calculated?
🏛️ Why is it important?
The EBITDA margin reveals how much operating income a company generates per dollar of revenue – independent of capital structure and tax effects.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBITDA margin reflects strong core profitability – before accounting distortions.
- It allows for effective comparisons across companies and sectors.
- A stable or growing margin signals efficient cost control and business scalability.
📘 EBIT Margin
📈 What is it?
The EBIT margin shows what percentage of revenue remains as operating profit after depreciation but before interest and taxes.
🧮 How is it calculated?
🏛️ Why is it important?
The EBIT margin reflects a company’s core profitability while accounting for capital intensity (e.g. machinery, infrastructure). It’s especially useful for comparing businesses with different levels of depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT margin shows that the company remains efficient even after factoring in depreciation.
- It’s especially relevant for capital-intensive industries.
- Stable or rising EBIT margins over time are a strong indicator of pricing power and business quality.
📘 Net Margin
📈 What is it?
Net margin shows how much of a company’s revenue remains as bottom-line profit after deducting all costs, interest, taxes, and depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
Net margin reflects a company’s overall efficiency – across operations, financing, and taxation. It shows how much actual profit is generated from each dollar of revenue.
🧮 Calculation
🎯 What does this mean for investors?
- A high net margin means the company is not only strong operationally but also manages financing and taxes efficiently.
- Peer comparisons reveal business quality and competitiveness.
- Declining margins despite revenue growth can be a red flag for rising costs or inefficiencies.
📘 Free Cash Flow Margin | ex SBC
📈 What is it?
The Free Cash Flow Margin shows how much free cash flow a company generates relative to its revenue. In simplified terms, free cash flow is calculated as operating cash flow minus capital expenditures. The Free Cash Flow Margin ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted metric.
🧮 How is it calculated?
Free Cash Flow Margin ex SBC = (Free Cash Flow − SBC) ÷ Revenue × 100
🏛️ Why is it important?
The Free Cash Flow Margin shows how efficiently a company converts its revenue into free cash flow. Strong free cash flow can provide financial flexibility for dividends, share buybacks, debt repayment, or further investments. The ex SBC version additionally accounts for the economic impact of stock-based compensation and therefore provides a more conservative view of cash generation from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A high Free Cash Flow Margin shows that a company converts a high proportion of its revenue into free cash flow.
- This can provide greater financial flexibility for dividends, share buybacks, debt repayment, or investments.
- The Free Cash Flow Margin ex SBC additionally accounts for potential shareholder dilution from stock-based compensation.
- The long-term trend is particularly important. Declining margins can, for example, result from higher investments, changes in working capital, or weaker operating performance.
📘 Equity Ratio
📈 What is it?
The equity ratio indicates what portion of a company’s total assets is financed by shareholders’ equity – in other words, how much it relies on its own capital.
🧮 How is it calculated?
🏛️ Why is it important?
A high equity ratio reflects financial strength and stability, especially during downturns. It’s a key indicator of a company’s solvency and long-term risk profile.
🧮 Calculation
🎯 What does this mean for investors?
- Companies with high equity ratios are generally more resilient and less dependent on external debt.
- Low equity ratios can signal higher risk or aggressive financial strategies.
- Important: Always assess the equity ratio in combination with the return on equity (ROE). This shows not just how stable the company is – but also how efficiently it uses shareholder capital.
📘 Return on Equity (ROE)
📈 What is it?
Return on equity (ROE) shows how efficiently a company uses its shareholders’ equity to generate profit. In other words: how much net income is earned per dollar of equity.
🧮 How is it calculated?
🏛️ Why is it important?
ROE is a core profitability metric. It helps investors understand whether a company delivers attractive returns on the capital provided by its shareholders.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROE indicates that the company is using its capital efficiently and profitably.
- It’s especially meaningful for capital-intensive businesses or firms with high equity bases.
- Important: A very high ROE can also result from high debt levels – always interpret it alongside the equity ratio to assess financial health.
📘 Return on Capital Employed (ROCE)
📈 What is it?
ROCE measures how efficiently a company generates profits from its total capital – including both equity and interest-bearing debt.
🧮 How is it calculated?
It evaluates the return on all capital employed, regardless of how it’s financed.
🏛️ Why is it important?
ROCE is ideal for comparing companies with different financing structures. It shows how well management uses capital to create value for both shareholders and creditors.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROCE means the company uses its capital efficiently – regardless of whether it's funded by debt or equity.
- The higher the ROCE compared to peers, the more value the company creates with its invested capital.
- Especially relevant for capital-intensive sectors like industrials, energy, or infrastructure.
📘 Return on Invested Capital (ROIC)
📈 What is it?
ROIC measures how efficiently a company generates returns from the capital invested in its core operations – regardless of whether the capital comes from equity or debt.
🧮 How is it calculated?
- NOPAT = Net Operating Profit After Taxes
- Invested Capital = Operating assets minus non-interest-bearing liabilities
🏛️ Why is it important?
ROIC is one of the most accurate indicators of capital efficiency. Unlike return on equity, it is not distorted by leverage and shows how much value is created for all capital providers.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROIC shows how effectively a company uses the capital that is truly invested in its core operations.
- Unlike ROCE, ROIC focuses only on the capital that is actively used to run the business – and that requires a return (i.e. interest-bearing).
- Especially useful when comparing companies with large amounts of excess cash or non-interest-bearing liabilities – giving a more realistic picture of capital efficiency.
📘 Leverage Ratio (Debt-to-Equity)
📈 What is it?
The leverage ratio indicates how much a company relies on interest-bearing debt (such as loans and bonds) relative to its shareholders’ equity.
🧮 How is it calculated?
🏛️ Why is it important?
This ratio helps assess a company’s financial structure and risk profile. High leverage can enhance returns – but also increases exposure to interest rate changes and financial stress.
🧮 Calculation
🎯 What does this mean for investors?
- A low leverage ratio signals financial strength and independence.
- A higher ratio can improve returns in good times but increases risk during downturns or rising interest rate periods.
- 👉 Always interpret in the context of industry, capital intensity, and interest rate environment.
📘 Earnings per share (EPS)
📈 What is it?
Earnings per Share (EPS) shows how much profit is attributable to a single share – and is one of the most important metrics for evaluating a company's performance.
🧮 How is it calculated?
The diluted share count reflects potential new shares that could be issued through options, convertible bonds, or other rights.
🏛️ Why is it important?
EPS is the basis for many key valuation metrics like P/E ratio, PEG ratio, or payout ratio. It enables comparisons of profitability across companies, regardless of their size.
🧮 Calculation
🎯 What does this mean for investors?
- EPS captures per-share profitability and is especially useful for comparisons over time or with analyst estimates.
- Rising EPS may signal consistent growth or share buybacks.
- Important: Always use diluted EPS for more realistic valuations – especially in companies with stock-based compensation.
📘 Free cash flow per share (FCF per share)
📈 What is it?
Free Cash Flow per Share shows how much free cash flow a company generates per outstanding share – after investments, but before dividends or debt repayments.
🧮 How is it calculated?
Free cash flow is calculated as operating cash flow minus capital expenditures (CapEx).
🏛️ Why is it important?
FCF per Share reveals how much real cash is available per share – useful for dividends, buybacks, or reducing debt. Unlike net income, free cash flow is harder to manipulate and often seen as a more reliable metric.
🧮 Calculation
🎯 What does this mean for investors?
- High FCF per share signals strong financial flexibility.
- It shows how much capital the company can effectively reinvest or return to shareholders.
- Particularly relevant for dividend payers and capital-efficient businesses.
📘 Short interest
📈 What is it?
Short interest indicates how many shares of a company are currently sold short – that is, borrowed and sold by investors who expect the price to decline.
🧮 How is it calculated?
It reflects the percentage of a company’s shares that are being shorted relative to the total shares available.
🏛️ Why is it important?
Short interest serves as a sentiment indicator: A high value may signal skepticism or bearish expectations – but also increases the potential for a short squeeze if prices rise unexpectedly.
🎯 What does this mean for investors?
- Low short interest usually indicates market confidence in the company.
- High short interest can be a warning sign – or an opportunity if sentiment shifts.
- Especially relevant in volatile markets or ahead of key earnings releases.
📘 Employees
📈 What is it?
The employee count shows how many people a company employs worldwide – offering insights into its size, structure, and business model.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess operational scale, labor intensity, and cost structure. Combined with revenue and profit, it enables key metrics like revenue per employee or productivity.
🧮 Calculation
🎯 What does this mean for investors?
- A high headcount can signal operational complexity – but also significant growth capacity.
- Revenue per employee is a key indicator of efficiency.
- Especially useful for comparing tech, industrial, or service-heavy companies.
📘 Revenue per employee
📈 What is it?
Revenue per employee indicates how much revenue a company generates on average per employee – a key measure of efficiency and productivity.
🧮 How is it calculated?
The employee count is typically taken from the most recent annual report.
🏛️ Why is it important?
This metric helps compare business models – especially between labor-intensive and technology-driven companies. A high value suggests automation, operational efficiency, or strong value creation per head.
🧮 Calculation
🎯 What does this mean for investors?
- A high revenue per employee indicates a scalable and margin-strong business model.
- A low figure may reflect labor-intensive operations or lower value-add.
- Especially helpful when comparing tech companies to industrial or service sectors.
ChemoMetec Stock Analysis
Analyst Opinions
12 Analysts have issued a ChemoMetec forecast:
Analyst Opinions
12 Analysts have issued a ChemoMetec forecast:
ChemoMetec Events
Past Events
|
NOV
6
Q1 2027 Earnings Call
11 days ago
|
|
SEP
11
2026 Earnings Call
2 months ago
|
StocksGuide Free
ChemoMetec — Q1 2027 Earnings Call
1. Management Discussion
Good day, and welcome to ChemoMetec's conference call.
[Operator Instructions] Please note that today's conference is being recorded.
I would now like to turn the conference over to ChemoMetec's CEO, Martin Helbo Behrens. Please go ahead, sir.
Hello, everyone, and welcome to Q1. With me today, I have, first, of course, a disclaimer. We have to show everyone, but we'll quickly move on to the next slide, where today, I have our CFO with me, who will actually start here at first giving a presentation on the numbers from Q1. And then as usual, I will go over the commercial aspect. So, over to you, Phillip.
Thank you, Martin. Let's jump into the financials. As always, all numbers I'll refer to will be in DKK. Revenue for the quarter increased by 28% to DKK 160 million, while EBITDA increased by 46% to DKK 100.3 million. This resulted in an EBITDA margin of 63% compared with 55% last year. The development was mainly driven by higher revenue, providing operating leverage, continued cost discipline and improved gross margins on our XM products.
Looking across our product portfolio, Instrument sales were the main growth driver this quarter. Revenue went up with 61% to DKK 65.6 million. The main driver for this area was the XM products, especially our NC-203 that accounted for DKK 20 million in revenue this quarter compared to 0 in the same quarter last year. Consumables increased with 8%, while services increased by 22%.
We saw growth across all of our geographical segments, regions. North America increased by 25% to DKK 88.6 million. Europe increased with 24% to DKK 53.3 million, while the rest of the world increased by 71%. The increase in the rest of the world is mainly driven by distributors that built up their inventories of instruments. That also means North America remains our largest market with just above 55% of group revenue, Europe with -- followed by Europe with 33% and the rest of the world with 11%. So overall, the geographical mix is quite stable quarter-over-quarter.
Our core LCB business increased by 31%, so strong performance here. Revenue ended at DKK 153.4 million, and it represents 96% of group revenue. And the smaller animal semen, beer and milk business area declined by 11% and represented 4% of group revenue.
Following the strong first quarter and the continued positive development into Q2, we upgraded our full year guidance this week. We now expect revenue to be between DKK 570 million and DKK 605 million, EBITDA between DKK 335 million and DKK 360 million. And investments, we still expect approximately DKK 120 million. The upgrade is mainly driven by the stronger-than-expected instrument demand, particularly for the NC-203 and then the continued lower cost base.
And with that, over to you, Martin.
Thank you. Not the worst quarter. So over here to the market conditions. And again, we do see some growth in the CAR-T area. We are very excited, of course, about the previous generation. But again, as you can also see here, there is some competition. And as you probably also have read, you have Yescarta from Kite with some competition from some of the other ones, Carvykti and Breyanzi. But overall, what we like to see and what we also hear in the field is our customers are expecting growth, which means, of course, that we're also expecting to sell more instruments and more consumables and more services to these customers. And overall, it is quite important to see that the revenue keeps growing in this segment.
If we move over to patients treated, it's also something we follow because as everyone knows, every time one patient is treated basically, they will use one cassette. Of course, we do not have all the approved cell therapies, but we usually say that we have 9 out of 10 using our products. And as you can see here, just as of Q2, it looks like an all-time record again for the approved cell therapies, and this is something which is, of course, very good for ChemoMetec.
On the funding side, we still only have the numbers from first half of the year. But it seems like there is some recovery in the field. And also when we're talking to customers, when we are basically in the field, we do also see some recovery. I do remember a couple of years ago when I went with our team around the world, we did see a lot of layoffs. We did see many customers saying, yes, well, we do not have the money right now to spend on instrumentation. We're not basically looking to scale right now, whereas of today, I will say it looks better, also the budgets are better. So definitely some recovery in the industry.
Also, what we're looking at because you can probably imagine using our instrumentation, you need staff. So if you lay off a lot of staff, it usually means you'll also cut some projects, which means less instruments, less usage and which is also, of course, affecting our revenue. So this is also in line with what we're seeing in the field. It looks better, and this is definitely something to follow.
Again, on the long run, it's very good to see that we're seeing an increase again in active trials. This is very important for the industry. Again, only 49 approvals in the world. We got 9 in this year so far. So again, we still see approvals coming out. And of course, quite -- we're looking quite forward to the future basically.
If we move over to product and partnerships, this is an important part for ChemoMetec, but we have basically launched our new instrumentation here, which is also a decent amount of the growth you see this last quarter. But if we're looking first at the XM40, we do have this instrument specifically target for the bioprocessing area. And also in the last quarter, we actually have started to penetrate bioprocessing. We have sold a decent amount of instrumentation to the bioprocessing area. So this is, of course, something we're very happy for.
Looking at the 40 and the 30, basically, those instruments can be used in bioprocessing, but mainly the 40 is targeting that area since a lot of instrumentation previously and competitors are based on the carousel we also have in the 40. The 30 is meant for automation, and we have seen a lot of customers reaching out saying they're looking into automation. But again, it takes time with automation. They might have running manufacturing today where they're not used to manufacturing. So actually transforming from manual to automated setups takes time. But we do see many larger companies having specific departments now trying to develop automation flows, and we have a lot of inbound leads on the 30, and we do really believe the future is automation.
The 203, which is an upgrade basically to the 200 and the 202, is based on the same platform technology-wise as the 40 and the 30. It's cassette based, which many customers like. And overall, when we go into the field now with the new platform, what our customers really love is basically that previously, you had to validate one instrument. And then if you wanted to change that method, you need to do a revalidation. Now we have actually made it possible to have a different way of handling your sample. You can have the carousel, you can have the automated way with the satellite, the 30 and then the cassette-based 203. And you only have to validate the platform once, then they actually align across, and that's something our customers really love. And that's also some of the USPs where we're actually competing against other instruments out there.
On the strategic partnership side, it's not a secret that penetrating bioprocessing could be difficult. It's a very established area, and you need good relationships with the customer to basically show your product. So what we have learned is you need to build combined solutions. And we're trying to do that with Tecan and Hamilton and Roche [ for. ] We have more coming up, some exciting partnerships. But basically, what customers want is they do not want to contact different vendors and then do the automation integration themselves. They want to buy off-the-shelf solutions. So it has been a very important part for us to basically team up with all these partners. And remember, you see the partners here today, but we have been working with them for a couple of years now to do the integration, the validation to basically be ready to sell these products. So more of that coming in the future for sure.
Then we have product development, which is always an exciting area. And as you know, not only in the future do we want to be a cell counting company. It's important for us to basically show our capabilities, which means we can actually build end-to-end automated sample management systems actually combined by hardware and software. And mainly what you see here is one of our ideas to customers. It's a modular end-to-end system where you can basically have a lot of high-throughput cell counts, including other instrumentation than our own products, but also analyzers and whatever you need. And mainly in the future, we hope that customers, which we already know, will implement these end-to-end systems so they can basically cut the cost, which is one of the biggest, you can say, the biggest issues today with manufacturing of CAR T cell therapy.
So we have big hopes for these systems. And it's not more than a couple of weeks ago, we showcased this product last time. It was our XM user days where we fly all our larger customers. This time it was in France, and we showcased our new technology. We got some feedback on this specific sample management system, and we hope to start testing next year with customers.
Next up, we have software and integration. And last time, I'm not sure if you know, but we only had software here, but now we added integration. And that's because what we have learned the last year and 2, is that many, many companies out there can do software. They can integrate and they can show some data. But what we have learned is what the customers actually want is the data generated on our hardware. So we have started to already sell API licenses in the field, which means if customer wants to get the data out of our computer, out of their computer of their system into another system, today, they actually pay an API license. And of course, in the future, we're going to add the XM Octopus on top of that. But today, we have already sold for a couple of million API licenses just for integration. And in the future, all XM30s will come out with API license. So that's a new revenue stream for us.
And then we are ready for some questions, which I guess there will be many of. Thank you.
[Operator Instructions] We will take our first question and the questions come from the line of Mads Brinkmann from Berenberg.
2. Question Answer
Congrats on a really strong quarter. Just starting with 2, please. If we look at the instrument sales, obviously, they were very strong. But if I'm just playing the devil's advocate here a little bit, obviously, very much driven by the 203. I'm just thinking how should we think about the XM sales? Because if I look at XM year-over-year, I mean, it's more or less flattish. So I'm just thinking about how should I think about the development of XM or XcytoMatic as a whole, excluding 203 for the remainder of the year?
And then the second one, please, if I just look at your guidance, I know you just upgraded it again. But if I look at sort of the implied growth based on a very strong growth in Q1, the implied growth for the remainder of the year is 6% to 5%. I'm just thinking what it would take for the guidance to reach the lower end. It seems quite cautious, especially given the sort of easy comp that you have in Q2. That was all for me to start with.
Yes. Thank you, Mads. I can take the commercial side, Phil, then you can do the guidance. But first of all, when we're selling our new platform, it's important to say that previously, we went into the market with the 200 or 202, and they basically implemented that for every single department. Now we do see it very differently. We do see that customers might be implementing the 40 in R&D, then in clean rooms, in process. They like the closed container system, which is the 203, where they just have no way of basically having any contamination with our instrument. And then in QC, you have a lot of testing where you then want to automate that testing with a 30 and a liquid handler system. And right now, in process is the big part of the manufacturing.
So from our point of view, when we go into the market, it's not important if the customer wants the 30, the 40 or the 203. The big USP is basically they can choose whatever they want. And what we have learned is they will actually want different instruments for different departments. And right now, the 203 is what they want, but also we have actually sold some 30s and some 40s. I will say the 30 is more long term because it's automation, and you don't automate something overnight.
So some of these sales you see right now is just for the validation. It's just for the first integration. At some point, they will buy in bigger bulks. And of course, we're looking very much forward to that. But that can take a year or 2 before they really start buying a lot of 30s for those flows. So overall, I think you should look at it as a platform. Of course, there is a different pricing between the products. But from our point of view, it's just a big USP to sell a platform. So we're just happy whatever they buy. So that will be the answer to the first question.
I think, Phillip, you can do the guidance then.
Yes, definitely. So thank you for the question, Mads. I just want to reiterate that Q1 was exceptionally strong, and we're not going to extrapolate the 61% growth on instrument sales mechanically for the full year because the growth was primarily driven by the NC-203. We also had some delayed and postponed instruments order that was executed during this quarter. It is difficult to predict the future. We're really doing our best here. But our current guidance reflects the current expectations for the year, including expected revenue and also the cost development.
I will add to that also that last year, we had a similar situation. And this year, of course, we want to be conservative. We want to make sure that we don't have to downgrade. So we have learned from the past. And I think it's only 6 months ago, we had a lot of, I won't say, angry investors, but we had some. And I think we have learned to basically be very transparent and say it's very difficult for us to predict the future here because our visibility is so low. So of course, we're hoping for the best, but it is crucial for us that we don't have to downgrade again. So we have learned from the past, and that, of course, is also some of what you're seeing here.
That's perfect. That makes sense. Just one follow-up, please, on the instrument side. Obviously, I think you mentioned it yourself as well, just the rest of the world, obviously very, very strong as well, but you also mentioned that some distributors are building up inventories. Maybe just if you could add a few comments on that. I mean how -- just are you adding any distributors? Is that part of it? Or is it essentially just distributors taking in more stock? And how should we think about that for the rest of the year? Or is it more sort of a very strong Q1 impact and maybe we should expect it to come down a little bit for the rest of the year?
Yes. So to be very transparent, we have also made a strategic change in the rest of the world. So we have changed pricing from January 1. So they align with Europe and U.S. from that point of view -- from that time, sorry. So of course, they have bought instruments now at the current pricing and to hope not to spend too much with the new pricing. So it is a timing thing, but it is crucial for us to say, in the future, we sell to bioprocessing, we sell to global customers. So the pricing will be the same globally, and that has something to do with the pattern you have seen in Q1.
Our next questions come from Jesper Ingildsen from DNB Carnegie.
A couple of questions from me as well. So on the NC sales that you recorded in the quarter, could you just elaborate a bit if that sales is benefiting from sort of like last buys ahead of the end of life of the NC-200 platform coming up here in April? And yes, just more generally sort of like play out ahead of that cutoff in terms of April?
And then on the XM sales, including NC-203 and 30, 40, could you maybe also just elaborate a bit on how much of this is related to some of the larger orders that led you to downgrade your guidance last year and if that's something that's finally coming through?
And then maybe just a last one. You do also comment that you have had a strong start to Q2. And as alluded to before by Mads as well, I mean, you also have easy comps coming into November due to the U.S. government shutdown last year. Could you just elaborate a bit about this initial strong start and to some extent, if you are seeing some larger budget flushes this year coming into the latter part of the calendar year?
Yes. So on the order side, so mainly, yes, 1 or 2 of the delayed order from last year has been realized this quarter. But again, they have only bought some of the instruments, some of these customers are major customers. So of course, we're still expecting more. And to be honest, this is only the beginning and nothing has changed from what we have said over the last, I would say, since I started as a CEO. This takes time. We have some validations. We have learned that they are a little bit slower than we expected. Everything got basically postponed by 1 quarter. So that's the basics here.
On the last time buy subject, so mainly, what's going to happen now and here is we'll start selling a few NC-203s to many, many different customers. They'll start their validations. And while they do that, they will have to buy NC-200s for the time until they do the transformation to the 203. So every single NC-200 we sell right now will be replaced by 203 in a year or 203 (sic) [ 202 ]. So mainly, we have a lot of customers starting the validation now. We haven't replaced any manufacturing sites with NC-200s yet. This is only the beginning. And they will have to buy the amounts they need of NC-200s until they can do the transformation. So we will see some bulk orders on the NC-200 in Q3.
How many? It's almost impossible for us to say. We don't basically have the numbers. But of course, we have to expect some since this is their growth in the next couple of years, they'll have to buy for. And then later on, they'll have to replace those ones with the 203. So that will be the answer to that.
On the last one, Phillip, I think you can take that.
On the -- sorry, I was not -- could you please take that?
Yes, sure. So I think everyone is basically looking at strong first 4 months. And again, I can only repeat what I said to Mads. It's very difficult for us to predict. We want to be on the safe side. And I know if you just multiply Q1 with 4, then you have a very different number. But basically, for us, very low visibility. We don't want to disappoint anyone. Do we hope for more? Of course, but that's the case right now.
Okay. Just quickly coming back to the last buys at the end of life here in April. Do you include anything from that in your guidance at this point in time? And it sounds like you're expecting mostly to benefit from this in Q3 of your financial year, if I understand it correct.
Yes. No, we have not included it in our guidance. Of course, we have the usual running business. But if you see a bulk coming in from many companies, no, we haven't included that because we simply don't have the orders. And we have learned from the past, don't expect too much and then be disappointed. So it will be hopefully a positive surprise.
We will now move on from the conference call questions to those submitted via the webcast.
I would now like to hand over to Frederikke Hvidberg, who will read out the webcast questions. Thank you.
Okay. So the first question we have is from [indiscernible] who is asking, can you elaborate on the XM30, 40 sales figures in Q4 last fiscal year compared to Q1 this year?
Phillip?
Yes. So we saw a slight increase in the XM30 and the XM40 compared to the last quarter that we ended in the last fiscal year. So again, the main growth driver here is the NC-203. So it's kind of flat from last consecutive quarter to this quarter.
And the next question is from [ Knut Hansen, ] who is asking, what is the percentage of your revenue used for future R&D?
So again, we expect DKK 120 million in investments during the year. Half of that, I would say, approximately is for product development. So around 10%, I would say, is from the revenue is spent on R&D projects.
The next question is from Ludvig Lundgren, who is asking, consumable sales recovered after a slower period. Is it fair to extrapolate this growth considering the rather easy comparisons in the segment ahead?
Yes. I think it definitely depends on the amount of treated patients. But again, as we showed in the presentation, it looks like it will increase. So of course, when our patients are doing better, when funding is better, then, of course, our consumable sales will also be better. So yes, we hope for continued growth on the cassettes, and it looks decent, yes.
And then we have one more from Ludvig, who is asking, you highlighted some backorder instrument deliveries. Is it possible to elaborate on the magnitude of these?
It's difficult because I will say it's not a lot. It's mainly what we sold this quarter is a few instruments to many customers, which is also what we actually want because you can imagine if you want a lot of replacements of the 200 later on, you want to get started with a lot of validation. So we haven't received any larger orders. I think the largest one has probably been 20. So it's still to come, but it's very good to see many customers buying a few because we know what that means. It means selling a lot in the future.
Then we have one from [ Fredrik Aanla ] who is asking, NC-203 sales were about 4x the Q4 level, and you mentioned distributor stocking in some markets. How much of Q1 demand reflects end customer purchases versus distributor inventory? And what have you seen in orders since quarter end?
We mainly sold a few NC-203s to distributors. It hasn't really penetrated in Asia yet.
Then we have a question from [ Michael Howen ], who is asking, as the NC-203 gradually replaces the existing NC-200 installed base, what will sustain the current level of revenue?
Yes. Hopefully, it will mean that we can do more upselling because the whole new platform will also have what we call first, the API license, which means you are able to integrate into our instrumentation. First of all, means you can control the instrumentation, but you can also extract data. So mainly today, when we sell an XcytoMatic product, our customers are paying a fee for API licenses, which is 100% margin. So that's also why you see increased margins. And then afterwards, they'll basically also pay for a yearly subscription on service and support for that API license. And later on, we will be launching XM Octopus with a lot of features where we'll also do some upselling. We have showcased XM Octopus to all our customers in France at the XM user days, and we have a lot of demand for it.
So we'll be starting the test very soon also because actually, one of the customers came to me and said, specifically what they do right now is they're doing a lot of testing worldwide. And we have this customer in Germany who are also testing in Singapore, he's also testing in California. And when they do the test today, they have to extract the data and send it. The problem was when he came in the morning, they forgot to send it. So he lost a day. And with XM Octopus, every time you do a test, a sample, you'll actually have it synchronized so everyone can basically extract in real time.
So this is very useful for our customers. We have big hopes for it. We need to make sure it works perfectly for them, but we'll begin testing in 2027, and we have a big queue for it already. So it's quite exciting. And basically, that's the XcytoMatic platform in the future, you will basically be able to do a lot of upselling compared to today. So it will increase consumable service and software spending per instrument.
Then we have one last question left, which is from Peder Philipsen, who is asking, following the Tecan partnership, are you actively pursuing similar strategic partnerships with other major players in the bioprocessing and life science industry, such as Sartorius, Thermo Fisher and Danaher? And should we expect further partnership announcement as part of your growth strategy?
Yes, it's definitely a strategy. And what's important for us is when we do the partnerships, they are nonexclusive. So what we hope for is one day when our customers are approaching a liquid handler company, a bioreactor company, whatever, they will basically offer our XcytoMatic platform and be sold combined with the solution they offer. So first of all, that will increase our margins because it's less cost per sale. And also, you will have -- you'll get this huge exposure to a market where today with a limited amount of employees we are, you'll get a huge help here. So that's also some of it we have here with Roche. They will present our product. They will basically showcase it to customers. And just that, of course, will increase our inbound leads. And we definitely -- we definitely believe that, that is how to penetrate the bioprocessing market, yes.
All good?
That was the last question. So thank you, everyone, for joining.
Perfect.
Thank you for joining today's conference call. This concludes the presentation.
ChemoMetec — 2026 Earnings Call
1. Management Discussion
Okay. It is now 3:00 p.m., so let's get started. Thank you all for joining, and welcome to ChemoMetec's conference call. Today, CEO, Martin Helbo; and CFO, Phillip Massie Price will take you through this year's annual report, followed by Q&A where you can type in questions, and then I will read them out loud.
Okay. So let's get started. Over to you, Martin.
Yes. Thank you everyone, and welcome to conference call. Today, I have with me our new CFO, Phillip, who will give a short presentation here at first. But also I want you to basically give us a little bit of feedback on this new setup. We have had a lot of feedback from investors on previous conference calls. So today, we're trying something new and hope you will provide us with some feedback afterwards.
So over to you, Phillip.
Thank you, Martin. Just a few words from my side, as this is first earnings call here at ChemoMetec. I joined the company in August as a CFO, so I've now been here for a little more than a month now. I can tell that it's been a busy start but also a great opportunity to getting to know the company and the organization. And I really look forward to the journey ahead.
With that, let's turn to the financial performance for the fiscal year 2025, '26. All numbers I'll refer to will be in Danish crowns. Revenue for the year came in at DKK 511 million, which is equivalent to 3% growth compared to last year or 7% at constant exchange rates. EBITDA ended at DKK 281 million, 9% growth compared to the year before. And our EBITDA margin increased from 52.1% to 55%, equivalent to 2.9 percentage point increase, which is mainly explained by the increase in revenue, improved profitability and a reduction in staff cost.
Looking across our product categories, the main growth driver for the year was our instrument sales. Our instrument revenue went up with 13% compared to the year before, which was mainly driven by our sales of XM trucks, including NC-203, that increased from DKK 27.7 million last year to DKK 68.1 million this year. Our service revenue increased by 4% and consumables declined by 4%. The decline in consumables is mainly explained by the U.S. federal government shutdown in the fall of 2025, during which several of our largest customers saw a decline in number of patients treated.
Looking at the geographical development. U.S. and Canada, our largest market decreased by 6% in reported terms, however, increased slightly by 1% at constant exchange levels. Europe increased by 14%, while we saw growth of 21% in the rest of the world. Looking at our 2 business areas. Life Science continued to grow with revenue increasing by 6% to approximately DKK 485 million and is now representing 95% of group revenue. Our animal semen, beer and milk declined by 32% to approximately DKK 26 million, reflecting our continued exit from this market.
And looking specifically at Life Science, it's worth noting that the reported growth does not fully reflect the underlying development in our core business. During the year, we were impacted by lower activity among some of our largest U.S. customers, including the checks from the U.S. government shutdown as well as some larger players leaving the market. This naturally had an impact on our consumable sales in short term. And finally, also reminding the negative FX impact, as mentioned earlier, the underlying growth is more around double digits for this area.
We ended the year with a strong balance sheet. Cash position of around DKK 290 million, equity of approximately DKK 725 million. And during the year, we invested around DKK 100 million in growth initiatives, including software, automation, product development and our facilities here in lab. And finally, our ongoing share buyback program, we have repurchased 105,000 shares at year-end, equivalent to approximately DKK 39 million. As of today, we have repurchased around 206,600 shares, equivalent to 1.2% of the share capital.
Thank you, Phillip. And once again, a record year. And as I'll walk you through a hopefully, also a record year this year. First, I'll walk you through the market conditions than our products and product launch than at last product development before Phillip will take you through our guidance. We're first, market conditions, still really exciting to see all these approved CAR-T cell therapies doing well, mainly we still see growth. And you can though see here that some cell therapies are struggling a little bit. And the one, of course, doing best is heavily our customer. But again, it has been a year with less treated patients. And of course, that is also affecting our consumables.
Overall, we do see some recovery in the field. If you look at this chart, you can see that it starts looking better. Also, when you're in the field talking to customers, actually seeing what's happening, it's easy to see that the flow is definitely getting better. Also, we reported at the year-end that it starts -- we start to see more demand from our customers. And of course, that has something to do with the market. If you look at the start-up environment, which is important to us, we start to see some recovery, and that is, of course, crucial because many of our customers are still in preclinical Phase I and Phase II.
So of course, this is an area which is very important for us. We keep investing specifically at incubator sites where we are very well represented with our instruments. And incubators for those who doesn't know that is where usually you have shared labs. So you'll have early start-ups, maybe professor and an assistant, who are doing some exciting work. They will be then testing a lot, doing a lot of research and then adding our instrumentation into the SOPs. So we have been investing a lot, made sure that when this market is recovering, we have a lot of our products written in their SOPs. Also something interesting is the layoff trigger. I think when I trailed around a couple of years ago, we spoke to customers and started to see a lot of empty spaces in Enbridge, for example. We saw a lot of layoffs, which also layer -- and that, of course, with fewer people, they do less sampling also means less testing and in the end less sales from us -- for us.
So here, I think this is very positive. Also, when we're in the field, we start seeing customers hiring. We start seeing less empty spaces. If you move into the incubator space, you actually have everything occupied by now. So very, very interesting and very good news for the whole industry. As we've just said, we had some, I will say, it was pretty rocky back in November. And you can also see here with the cutting of NIH funding. We saw some clinical trials getting canceled and since we have a decent share of the market, of course, we get hit as well. Majorly, we also saw some of the largest companies out there, Novo Nordisk, Galapagos, Takeda actually exiting the market. And of course, that is hurting ChemoMetec's revenue as well.
Overall, though, we are seeing a recovery, a pretty decent recovery. And again, I think if we move on to the next slide, you can basically see the growth of this company. We only have 45 approvals, and if you look at this charge, sky is the limit. And of course, as we are seeing more approvals in cell and gene therapy specifically, of course, we will grow with that. But also, of course, we have the exciting opportunity for bioprocessing in the future, which I'll come back to you. If you move on to the products, we are now talking a lot about axiomatic and NC-203, and that's mainly because it is the future of the company. We have spent so much time in the field validating the 40, the 30 and the 203 million.
And I will say, I think many of you have by now read a lot of articles and interviews about our XM30 and XM40, and the feedback is amazing. The 203 is also very exciting for us since we have, of course, announced the discontinuation of the 200. So many customers who are used to the flow of the cassette-based instrument will basically replace the 200 with the 203, but also many of them are looking now into automating some processes with the 30. So it actually will be a combination of the 203 and XM30, I believe, in the future for cell therapy. Again, it was a record year for XcytoMatic. And I remember, I think it was just a year ago. I had many investors asking, can you even sell this product? Is it even good? And I think these numbers justifying that it's not only ChemoMetec now saying this product is sellable. A lot of customers feedback [indiscernible], you have seen it all, they love this product.
So hopefully, of course, in the future, we'll start seeing ChemoMetec to expand even more in this area. And as you know, we're also reporting that basically we expect most of our instrument revenue coming from XcytoMatic in the future. For the Q4, specifically, if you include NC-203, we have a record quarter, again, DKK 17.7 million. And of course, most of that revenue, not of course, but most of that revenue actually happened in June. So what we started to see with the discontinuation also with the market improvement and automation. We saw a lot of demand. And again, we mainly had more than 50% of our instrument sales coming from this area. So we are very looking forward to the future.
Again here, some extra numbers. Of course, the growth -- it's explaining itself, and we have, of course, a big hope for the new year. Mainly the trend, which happened in June and Q4 is something we expect to continue into next year, current year. And the key drivers are basically the replacement of the 200. We have sold thousands of NC-200 so many customers, they have to now basically start replacing which means, first of all, they need to make sure they can produce for the next 3 years with NC-200. So we are seeing some last time buys as well as actually some departments already starting to basically validate our NC-203 or XM30, XM40.
Automation, again, is very interesting, I believe, because when we start seeing replacements for the 200, we also have customers saying, well, it would be nice to automate some process flows now when we are actually looking into validation. So we do see a lot of customers doing validations between the Hamilton system and XM30 and also basically a Tecan system in XM30. It also helps that the market conditions are getting better. We can see that, and we can also feel that when we're negotiating I remember a couple of years ago, getting budget for a customer for XM40 specifically was almost impossible, where today, we do see it is easier for them basically to purchase our instrumentation.
And not only that, we do also have been working on some strategic partnerships. And the strategic partnerships is something you only have to do once. Specifically here, I mean the validation into their systems. We have been working very hot in this area to ensure the best possible agreement for ChemoMetec also for the future. And mainly, many of these partnership has happened through customer land because when we have been presenting our XM30, XM40 and 203 in the field, we've had customers saying, why don't you actually start integrating into other systems. So instead of buying specifically from ChemoMetec, we can buy a combined solution, a system. So we started talking to [indiscernible] and Hamilton, Roche, to basically integrate our product into a larger solution, and I think we will see a lot from this in the future.
And then over to product development, where we also have some exciting projects for the future. I think what we're trying to show is mainly that in the future, Nomadic won't only be a cell counter company because one thing is doing an on-site cell count, but many customers actually also are looking into how can we treat more patients? How can we scale this business. So mainly, we're trying to with this cell management system, for example, to automate some procedures to help them scale, to actually help them do way more testing than they're doing today. And I've met with many, many operators also Head of Operations, who sits in the future -- we don't want too many operators in the app, in the manufacturing. They actually won hands free. So it's basically the car manufacturing all over again.
Specifically here, you see our sample management system, but also with an integrated XM50. And we are hoping that customers can save a lot of money by basically buying our automated system, scale their samples, scale their production and actually produce cheaper cell therapies. And talking about automation, hardware alone is not enough. You also need a software to ensure you can cut some costs. I can tell you when we are on site, we usually meet service managers who are overseeing 7,000 instruments where they need to make sure their service, they work, they're up and running. They get to the dairy day. And the whole idea about XM Octopus came to life because of that because what they would love is a fleet management where you can oversee all your instruments, make sure everything is serviced. You can even see is it working as opposed to. Is anything wrong? And if anything is wrong, you can just contact the ChemoMetec service engineer.
So here by moving into the software area, it's basically customer is the customer demand, but also it just makes so much more sense because you can imagine, overseeing 7,000 instruments, which is not only ChemoMetec instruments, it's just a lot of work. So imagine if they can oversee just per system, and basically, look into that and service and everything, you will cut so much cost. Also with XM Octopus, instead of going into a lab to extract data, you can actually send the data by an API into a remote server. And by that, you can do QC approval, you can even do audits from FDA in there. So you have so many opportunities with this new software. And of course, we have big expectations for that as well.
And the next slide here, Phillip?
Thank you, Martin. So to wrap everything up. Our expectations for the fiscal year 2026, '27. We expect revenue of between DKK 545 million to DKK 575 million, equivalent to growth around 7% to 13% and EBITDA of between DKK 300 million and DKK 313 million. Also, we expect CapEx to be around DKK 120 million. So while we expect growth in both revenue and EBITDA our margin and also CapEx will be reflecting our continued growth initiatives.
With that, over to Q&A.
Okay. So let's start with the first questions. Jesper from DNB. Could you help us understand the assumptions behind '26, '27 guidance? Do you expect instrument sales, both XM and NC to be the main growth driver, while consumables and service continue to decline? And what would need to happen for you to end up at the upper versus lower end of the guidance range?
Yes. I'll take that one. And basically, the assumptions behind guidance is, of course, we have learned from last year. I think many, many investors, they reach out, of course, after our downgrade, and this is not something we are very proud of. So we have learned from that. So this year, we, of course, have seen some market improvements. We have a lot of exciting replacements to do. And mainly, we have looked into what is the worst case scenario here because we don't want to disappoint. What we expect is mainly the instrument sales to grow first because you have consumable and service growth, you need instruments to grow it first. We haven't basically had any expectations for Roche, Teek and Hamilton, those collaborations because we don't have any numbers. So mainly, that's, of course, an upside if that happens. So overall, we are looking at the guidance to say the running business itself -- how is that working out with the market and everything. But again, remember, the market improvement is basically only a couple of months old before it really started to take off. So we still have to see the trend, but we are cautiously optimistic about the future.
Okay. And the next question is also from Jesper. How do you view Novartis forcing some of its CGT programs, including YTB323 in DLBCL and PHE885 in multiple myeloma as well as BMS pausing some of its cell therapy programs in terms of what this signals for the broader CGT market and platforms such as TeCharge. And more specifically, have you seen any impact on ChemoMetec's activity or demand from Novartis BMS or related programs?
Yes. And of course, we have been reading about those programs as well. And I think if -- we're going back to the presentation, we saw more than 3,000 ongoing trials. So of course, when you have Phase I and Phase II trials, you have to expect some of them facing some issues. This is in vivo and in vivo is very different from ex vivo since the expansion happens inside the body. And I know they had some issues, but it's not something which causes too much stress or you can say we're -- from our point of view, this is what happens. So we hear it all the time. And of course, when you move into a whole new way of producing a drug, which is in vivo, you have to expect some issues throughout the clinical trials. So, no, we are not too nervous about that. And I think they're going to solve the issues, and we will see some exciting drugs in the future. And also, it is important to say that those platforms, Techar, for example, and next from BMS, they have many drugs on this platform. And so far, it has only been a couple of drugs facing issues. So the platform itself from Novartis and from BMS is to my understanding, not facing any major issues.
Okay. The next one is also from Jesper. You recently announced the discontinuation of the NC-200 platform with sales ending in April '27 and service ending in April '29. We hear that some labs have started making last time buys ahead of the April '27 deadline. Should we expect this to drive any meaningful uplift in instrument sales over the coming quarters?
Yes. And that's actually a very good question, Jesper. So thank you for that. So mainly, our visibility is -- might be 45 days. So from our point of view, of course, when we do a last time buy, we have some expectations for some last time buy. If you're producing with NC-200 and you know the last time buy is in April '27, you need to buy some instruments at some point. You basically cover up for the lag over the next couple of years. So yes, we expect some last time buy on -- related to the 200, and we also expect some NC-203 sales for validation. The difficult you can say, thing for us is basically to estimate it because last year, we tried to estimate it. We heard a lot of numbers, and we believed it. And this year, we're more cautious because we don't want to disappoint again.
And the next question is from Simon Larsson from Danske Bank. What about the push XM order triggering the PW last year, the old FY '25, '26 guidance set at DKK 565 million to DKK 580 million. We ended up at DKK 511 million, and now we have a new guidance pointing towards DKK 560 million at midpoint for FY '26, '27. Can you talk about what happened to those XM orders that you thought would end up in H2 last year? It seems like you're not counting on them materializing this year?
Yes. And mainly, it's because we haven't received the orders yet. So from our point of view, we will wait until we see the PO this year before we start reporting to any investors. So mainly still expect them at some point. It's very difficult for us to say when because these validations, we had a pretty great example last year in our annual report, I believe. Those validations, they take time. We have had validation running for a couple of years with many customers. Some of the sales you see right now is mainly from those validations running over a couple of years. So we also know at some point, these customers, they will buy more instruments. It's just very difficult for us to estimate. So right now, they're mainly not a part of the guidance since we are not familiar with the exact numbers and estimates even if they will arrive this year, next year or in 2 years. So that's the main case here.
The next question is from Ludvig from Arctic. And there's 2 questions. The first one, when it comes to the change in IFRS accounting, you highlighted a DKK 50 million effect on instrument sales in fiscal Q3. What was the effect in fiscal Q4, if excluding the accounting effects in '25, '26 and '26, '27, what is the implied sales growth range assumed in your guidance?
First of all, the DKK 50 million effect was one -- DKK 15 million, in fact, was a one-off, so we don't have any effect this quarter. So if we're looking at the expectation of our product development and investments, mainly, we are looking into investing more in our XM Octopus. We believe software is the future in this area. Also, we are looking to automation, sample management system, autosampler, we have some XM50 coming pretty soon. So we're looking to keep investing. And I think what's important for chemo medic is the next 5, 10 years, sell a lot of cell counters. But at some point, we have to look at what is the next growth leg from our point of view. So we're investing a lot in automation and in software, because we believe the future is systems and to sell a system, you need hardware, software, mainly automated. Also, of course, a big piece of this is for XM Octopus.
And the second question is, when it comes to the expected DKK 120 million product development expense in '26, '27, does this entail only capitalized investments?
Mainly is going to be CapEx, but of course, there will be some P&L as well. But mainly, it's going to be CapEx.
And the next question is from Peter from Posting Invest. Gosh, how far along are you with the collaboration? And when do you expect commercialization to begin? Is the validation process different or easier compared with standard customer validation losses?
Yes. And our expectations from Roche and for the Roche deal, I get the question a lot. And the difficult part from our point of view is, first of all, we're not allowed to talk too much about it. Second of all, we do not have any numbers. But we do expect -- we do expect to start selling next year 2027. And the validation process itself is difficult because when you're replacing driven blue based instrument, there will be differences between our method and driven Blue. Positive part here is we have spent some of our R&D expenses this year to basically develop protocols. So we are able to help the customer to basically do it an easier check transfer. So it will be some work for the customer. It will take time, but mainly, if you move straight to integrating it, that itself is not a problem. It's basically to replace an existing method that can be more difficult. But again, since the product will leave the market, they basically have no option. So they will have to do a validation, no matter what.
And the next question is from Mads from Bernberg. He has 2 questions. Number one, please help me understand what the underlying consumable growth was excluding legacy, for example, animal reproduction and government shutdown and excluding large customers leaving the market.
Yes. And it's a good question because if you look at the Life Science leg alone, the growth was pretty decent. And semens and our milk and beer has been struggling a little bit because it's not a focus area for us. Also, if you're taking those shutdowns into account, of course, it would be -- we'll be looking very differently. So we'll probably be a little above the 10% you see, I would say, probably around 15% for Life Science alone. Consumable wise, we did take a hit from those closures, so that would also have been a little higher. Yes.
And the second question from Mads. He wants an understanding of how many customers you're speaking to on the XM platform and how that compared to the beginning of the year. And in addition, how many potential instruments does that equate to?
Yes. we're talking to so many by now that I do not have the exact number, but it's in the 100s. So it's a lot. And I think the difference from our point of view to last year is that now we do not have to showcase the product before people show interest. We have a lot of customers and potential customers reaching out to they have heard about integration opportunities. So they definitely just want to see, can we just integrate XM30 into Hamilton, we have seen the webinar or et cetera. So the difference is definitely way more demand, way more, you can say, validations, and it's so many that I don't have the exact number, but way above 100.
The next question is from Yiwei Zhou from SEB. You mentioned that you're seeing improved demand towards the year-end. Can you elaborate if the demand improve for both NC and XM instruments?
And mainly, it's for XM and that is due to the discontinuation, the market improvements and many of those validations we have done prior to this year. So it's mainly XM and we definitely expect XM to be the leading instrument in the future, and it will also probably exceed NC next year.
And the next one is from Jesper from DNB. You are guiding for around DKK 120 million of CapEx in '26, '27, up from around DKK 100 million in '25, '26 and equivalent to more than 20% of revenue. how much of this relates to software development, how long should we expect CapEx to remain at more than 20% of revenue? And what would you consider a more normalized level once the current investments are completed?
Yes. And I'll say it always depends if our revenue goes through the sky, we will probably invest even more. We will have limited -- you have limits because you cannot keep investing unlimited. This year, we believe we need DKK 120 million. And mainly, the split is probably quite even between the different areas. But something our investors might not know is we're also spending a lot of R&D expenses for biology, creating protocols, easier tech transfers for our customers. So we have a lot of different areas. So the software itself might be 20%, 25% of our R&D expenses in the future, will we increase? It depends on the revenue and also actually the demand from customers because we expect to launch XM Octopus at some point. If they want something different, we'll build it. So I think this is an ongoing thing. And of course, I think you know is we have decent margins. We are pretty good with math. So if it makes sense, we'll keep investing. If it doesn't, we won't do it. So that's going to be the answer to that.
And then we have a question from Simon from Danske Bank. You stated in the report that before making their financial decision, customers expect documentation that the XM30, the XM40 and the NC-203 all produced comparable results for different cell types as well as country sites. You say it's a new development for customers to express these wishes. Does this mean that you're in discussions with customers looking to also replace competing products with ChemoMetec's cell counters and using ChemoMetec's cell counters as a platform solution.
Yes. And that's exactly what we're working on. That's also why the validation takes a little longer because usually, you might hear from a department, they want to buy 10 instruments. And then they say, "Oh, actually, we now are moving into global alignment because we actually want to replace everything with this new platform." So that what usually happens is that we're talking to one department, then other departments have other different instrumentation. And suddenly, this moves into a bigger project, and down the line, yes, we are expecting to replace a lot of competitor instruments and basically be the one cell counter in the field. I would say cell counter platform, actually.
And then we just have one question left. And the question is from Jesper from DNB. On the Roche collaboration, given the significantly higher throughput of XcytoMatic compared with the legacy [indiscernible], how should we think about the replacement ratio, is there any reason to expect something close to a 1-for-1 replacement, perhaps because customers typically operate the cell counter alongside acidic bioanalyzer. Or should we assume materially fewer XcytoMatic units will be needed?
Yes, and that's a good question again, Yes.So Mainly, if you want to integrate into the CDx bio analyzer, it's going to be a one-to-one replacement, but we have seen when we're replacing competitor instruments in the field that they can actually replace 2:1, which is also a big USP for the customer because our instruments are so fast. So it depends on the setup. But if it's a stand-alone, usually, they will replace 2 old instruments compare instruments with 1 instrument from ChemoMetec unless we're talking integration because then it is a one-to-one specifically.
And that was the last question for today. Thank you all for joining. See you in the next conference call.
Financial data from ChemoMetec
Revenue
Revenue is the sum of all sales generated by a company, e.g. for its products or services.
Revenue (TTM) metric explainedDirect Costs
Direct costs are the costs incurred directly in connection with the manufacture of the product or service.
Gross Profit
Gross Profit indicates how much of the revenue remains in the company after deducting direct production costs. If the percentage share of sales is calculated, this is referred to as the gross margin.
Gross Profit metric explainedSelling and Administrative Expenses
Selling, general and administrative expenses (SG&A) include all expenses for marketing and sales as well as the general administration of the company.
Research and Development Expense
Research and development costs (R&D) provide information on how much the company invests in the research and development of its products. The costs are particularly interesting as a percentage of revenue and in comparison to direct competitors.
EBITDA
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the company's earnings before interest, taxes, depreciation and amortization. The EBITDA margin is calculated as a percentage of sales.
Depreciation and Amortization
Depreciation represents reductions in the value of the company's assets (e.g. due to wear and tear on machinery).
EBIT (Operating Income)
EBIT (Earnings Before Interest and Taxes) is the company's profit before interest and taxes, also known as the operating income. The EBIT Margin is calculated as a percentage of sales at
.
Net Profit
Net Profit represents the profit or loss after deduction of all costs.
Net Profit metric explainedStocksGuide Premium
| Jun '26 |
+/-
%
|
||
| Revenue | 511 511 |
3%
3%
100%
|
|
| - Direct Costs | 87 87 |
4%
4%
17%
|
|
| Gross Profit | 424 424 |
3%
3%
83%
|
|
| - Selling and Administrative Expenses | 142 142 |
7%
7%
28%
|
|
| - Research and Development Expense | - - |
-
-
|
|
| EBITDA | 281 281 |
9%
9%
55%
|
|
| - Depreciation and Amortization | 30 30 |
41%
41%
6%
|
|
| EBIT (Operating Income) EBIT | 251 251 |
6%
6%
49%
|
|
| Net Profit | 202 202 |
16%
16%
39%
|
|
In millions DKK.
Don't miss a Thing! We will send you all news about ChemoMetec directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ChemoMetec Stock News
Company Profile
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for fluid cell count and analysis. It operates through the following segments: Instruments, Consumer Goods, Service, and Others. The Instruments segment sells NucleoCounter NC-100, NC-200, NC250, and NC-3000. The Consumer Goods segment offers disposable cartridges, disposable analysis chambers, reagents, and test kits. The Service segment provides service packages and its corresponding guarantees. The Others segment offers measuring modules and accessories. The company was founded by Hans Martin Glensbjerg in 1977 and is headquartered in Allerod, Denmark.
StocksGuide Premium
| Head office | Denmark |
| CEO | Mr. Behrens |
| Employees | 172 |
| Founded | 1997 |
| Website | chemometec.com |


